Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Royalty Pharma Stock: The Quiet Compounder The Market Is Still Mispricing (NASDAQ:RPRX)
Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728…
Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive a US$10 million milestone…
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
The Fidelity MSCI Health Care Index ETF (FHLC +0.47%) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (PPH +1.19%) offers a concentrated, higher-yielding focus on global pharmaceutical…
Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey Mumbai, India, Aug. 26, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals…
Drugstores Beat Sun Pharma's $10M Racketeering Suit
A New Jersey federal judge threw out Sun Pharmaceutical Industries Inc.'s suit against a group of pharmacies alleging they engaged in a criminal, years-long racketeering scheme that resulted in it paying... To view the full article, register now.
Odyssean LLC Acquires 21,401 Shares of Royalty Pharma PLC $RPRX
Odyssean LLC grew its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 65.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional…
Elmind Capital LP Invests $4.42 Billion in Urogen Pharma $URGN
Elmind Capital LP purchased a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 120,000 shares of the…
Algert Global LLC Decreases Holdings in BridgeBio Pharma, Inc. $BBIO
Algert Global LLC trimmed its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 27.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned…
ADAR1 Capital Management LLC Buys New Position in Urogen Pharma $URGN
ADAR1 Capital Management LLC bought a new stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional…
Castleark Management LLC Purchases Shares of 78,497 BridgeBio Pharma, Inc. $BBIO
Castleark Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 78,497…
Jupiter Topco LLC Makes New $1.05 Billion Investment in BridgeBio Pharma, Inc. $BBIO
Jupiter Topco LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 14,110,278 shares…
EFG International AG Makes New $6.12 Million Investment in BridgeBio Pharma, Inc. $BBIO
EFG International AG acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 82,172…
NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares of Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the firm's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $26.91, for a…
/afaqs/media/media_library/vi/AR4jM8vhg70/hqdefault-972320.jpg)
Lacto Calamine deepens its oily-skin expertise with strategic launch of light gel moisturization range
Piramal Pharma Limited's India Consumer Healthcare (PCH) business with its brand Lacto Calamine is venturing into light gel moisturizers. Building on its longstanding expertise in oily skincare, Lacto Calamine has launched a new range of light gel…
Woodside Energy: The $5 Billion Reset Helps, But I'm Not Buying Yet (NYSE:WDS)
Woodside Energy delivered solid H1 results, but valuation already reflects Scarborough's imminent cash flow and improved capital discipline. WDS shifts to a unified capital allocation framework, abandoning its $5B new-energy spending target and…
Receive a Daily briefing on Pharma Industry News
Get Started